2525 Development of human cell-based screening assays to detect subject-specific drug-response variability [PDF]
, 2018 Francesca Stillitano +4 more
openalex +1 more source
Molecular Oncology, EarlyView.PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source
Cutting edge strategies for screening of novel anti-HIV drug candidates against HIV infection: A concise overview of cell based assays. [PDF]
Heliyon, 2023 Gaikwad SY, Phatak P, Mukherjee A.
europepmc +1 more source
Cell-based assays for C99 interactions-Tango assays
BIO-PROTOCOL, 2017 Yan Yan +3 more
openaire +2 more sources
OPTIMIZATION AND VALIDATION OF A CELL-BASED TYROSINASE ASSAY FOR SCREENING OF TYROSINASE INHIBITORS
, 2011 Yan Ying Chan, Kim K H, S.H. Cheah
openalex +2 more sources
Establishment of live-cell-based coupled assay system for identification of compounds to modulate metabolic activities of cells [PDF]
, 2021 Kouichi Yanagi +8 more
openalex +1 more source
Molecular Oncology, EarlyView.This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan +9 more
wiley +1 more source
Discovery of New Glucose Uptake Inhibitors as Potential Anticancer Agents by Non-Radioactive Cell-Based Assays. [PDF]
Molecules, 2022 Hung HC, Li LC, Guh JH, Kung FL, Hsu LC.
europepmc +1 more source
High-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells [PDF]
, 2016 Bastien Gerby +21 more
openalex +1 more source
Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology
Molecular Oncology, EarlyView.Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts +8 more
wiley +1 more source